Patrick J Heron bought $9.0M of Mirum Pharmaceuticals (MIRM)
Executed Jan 23, disclosed Jan 27, 4 days later.
Over the 21 trading sessions from the disclosed entry session (Jan 27), the stock returned +12.1% (delay-adjusted); from the execution session (Jan 23), +10.0%. Derived: entry at the session's open, exit at the close 20 sessions later.
Patrick J Heron (Director) filed 2 Form 4 reports in the trailing twelve months (2 purchases, 0 sales), most often in MBX. Across 2 priced purchase filings, the average 21-session return was +4.9% from execution and +6.1% from disclosure (delay-adjusted; derived). The largest single filing was $12.0M of MBX (666,666 sh × $18.00, as filed), executed Sep 26 2025.
Healthcare · Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitat…
More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→